Extended indication Aflibercept monotherapy for first line treatment of Macular oedema in adults and elderly secondary to retinal vein occlusion.
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Aflibercept
Domain Neurological disorders
Reason of inclusion Indication extension IND
Main indication Eye disorders
Extended indication Aflibercept monotherapy for first line treatment of Macular oedema in adults and elderly secondary to retinal vein occlusion.
Proprietary name Eylea
Manufacturer Bayer
Mechanism of action Unknown
Route of administration Intravitreal
Therapeutical formulation Injection
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Type of trajectory Unknown
Particularity Unknown
ATMP No
Submission date April 2025
Expected Registration February 2026
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

This assessment does not indicate any potential inclusion in the package.

References NCT05850520

Expected patient volume per year

Patient volume

Market share is generally not included unless otherwise stated.

Expected cost per patient per year

Cost 3,500.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

References medicijnkosten.nl; GIPdatabank
Additional remarks De prijs inclusief BTW: Eylea injectievloeistof 40mg/ml wwsp 0,09ml €788,85 per stuk. In 2021 bedroeg de gemiddelde vergoeding per patiënt per jaar €3.585.

Potential total cost per year

Off label use

Off label use Unknown

Indication extension

Indication extensions Unknown

Other information